Sponsors

Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials

Biofidelity, a leader in innovative genomic solutions, and contract research organisation CellCarta, have announced a strategic partnership agreement to utilise Biofidelity’s Aspyre Lung in global clinical trials.

Aspyre Lung simplifies the detection of established non-small cell lung cancer (NSCLC) biomarkers by analysing both DNA and RNA from tissue and blood using a streamlined four-step workflow. Designed to run on existing qPCR platforms, it integrates seamlessly into laboratories globally and aligns with CellCarta’s mission to support global clinical trials through innovative genomic services.

Under the terms of the strategic partnership agreement, CellCarta will set up and validate Aspyre Lung in its European laboratories first, followed by its US-based laboratories; and will have non-exclusive rights to utilise Aspyre Lung for clinical trials globally. The partnership provides customers with revolutionary services leveraging both liquid and tissue biopsy samples, helping accelerate and facilitate rapid and reliable clinical trial enrolment.

"We are extremely pleased to enter into this strategic partnership with CellCarta to expand the use of Aspyre Lung to global clinical trials," said Biofidelity Co-Founder and CEO Barnaby Balmforth PhD. "At Biofidelity we’re actively working toward a future where more people around the world have access to the life-changing power of genomics. Partnering with CellCarta to make clinical trial enrolment faster and more efficient utilising Simplified Genomic Profiling (SGP) via Aspyre Lung moves us significantly forward toward fulfilling our mission."

"We are excited to embark on this partnership with Biofidelity," said Dusty Tenney, CEO of CellCarta. "CellCarta offers an extensive portfolio of biomarker testing services and tailored solutions for the pharmaceutical and biotech industry. The addition of Aspyre Lung to our capabilities marks an advancement in our mission to propel precision medicine with specialised laboratory services."

To learn more about Biofidelity’s Aspyre Lung, visit www.biofidelity.com/products/aspyre-lung-reagents/

 

Latest Issues

RSM / Path Soc 2026 Winter Meeting

The Royal Society of Medicine, 1 Wimpole St, London, W1G 0AE
20 - 21 January, 2026

BIVDA Regulatory Affairs Seminar

Grand Hotel, Birmingham
10 - 11 February, 2026

BDIAP Molecular Pathology Study Day

10 Union Street, London, SE1 1SZ
2 March, 2026

USCAP 115th Annual Meeting

Henry B. González Convention Center, San Antonio, Texas, USA
21 - 26 March, 2026

Microbiology Society Annual Conference 2026

ICC Belfast, Northern Ireland
13 - 16 April, 2026